Author:
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 288
Book Description
Unlisted Drugs
Author:
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 288
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 288
Book Description
Psychotropic Drugs and Related Compounds
Author: National Institute of Mental Health (U.S.)
Publisher:
ISBN:
Category : Psychopharmacology
Languages : en
Pages : 160
Book Description
Publisher:
ISBN:
Category : Psychopharmacology
Languages : en
Pages : 160
Book Description
Drugs Without Borders: Export of Finished Drugs
Author:
Publisher: Washington Business Information
ISBN: 9781932074185
Category : Drug control
Languages : en
Pages : 328
Book Description
Publisher: Washington Business Information
ISBN: 9781932074185
Category : Drug control
Languages : en
Pages : 328
Book Description
Generic and Innovator Drugs
Author: Donald O. Beers
Publisher: Wolters Kluwer
ISBN: 1454836091
Category : Law
Languages : en
Pages : 2154
Book Description
Completely updated, the new Eighth Edition of Generic and Innovator Drugs: A Guide to FDA Approval Requirements provides indispensable and practical insights into the FDA approval process. Youand’ll find comprehensive coverage of: Abbreviated new drug applications 505(b)(2) new drug applications Delaying approval of competing products FDA approval of biologic drugs No other book can cover the drug approval process as thoroughly, answering important questions like these: What is required to extend the patent of an FDA-approved product? When must a generic manufacturer notify the innovator manufacturer when submitting an ANDA or 505(b)(2) application? When does the FDA delay approvals because of patent claims, and when does it ignore patents? How can one challenge an FDA exclusivity decision? When can a manufacturer safely sell a drug without prior FDA approval? In what circumstances can a generic manufacturer obtain FDA permission to file an ANDA for a variant of an existing drug? When will the FDA waive or reduce prescription drug user fees? How can a company or an individual avoid debarment? What steps are necessary to comply with the FDAand’s Fraud Policy? When and how can a drug company take advantage of FDA accelerated approval procedures? What are the labeling requirements for exporting approved drugs? How have the changes made by the FDA Safety and Innovation Act, including the Prescription Drug User Fee Act, the Generic Drug User Fee Amendments and the Biosimilars User Fee Act, and the Generating Antibiotic Incentives Now Act affected the overall statutory scheme? Generic and Innovator Drugs: A Guide to FDA Approval Requirements, Eighth Edition provides step-by-step guidance of the approval process and expert interpretation of: The Hatch-Waxman Act (Drug Price Competition and Patent Restoration Act) The Medicare Prescription Drug, Improvement, and Modernization Act The Food and Drug Administration Modernization Act The FDA Export Reform and Enhancement Act The Biologics Price Competition and Innovation Act And more! AUTHOR NOTE Donald O. Beersand’ contributions to this publication were completed before he rejoined the Food and Drug Administration. He has had no part in writing and revising this Eighth Edition.
Publisher: Wolters Kluwer
ISBN: 1454836091
Category : Law
Languages : en
Pages : 2154
Book Description
Completely updated, the new Eighth Edition of Generic and Innovator Drugs: A Guide to FDA Approval Requirements provides indispensable and practical insights into the FDA approval process. Youand’ll find comprehensive coverage of: Abbreviated new drug applications 505(b)(2) new drug applications Delaying approval of competing products FDA approval of biologic drugs No other book can cover the drug approval process as thoroughly, answering important questions like these: What is required to extend the patent of an FDA-approved product? When must a generic manufacturer notify the innovator manufacturer when submitting an ANDA or 505(b)(2) application? When does the FDA delay approvals because of patent claims, and when does it ignore patents? How can one challenge an FDA exclusivity decision? When can a manufacturer safely sell a drug without prior FDA approval? In what circumstances can a generic manufacturer obtain FDA permission to file an ANDA for a variant of an existing drug? When will the FDA waive or reduce prescription drug user fees? How can a company or an individual avoid debarment? What steps are necessary to comply with the FDAand’s Fraud Policy? When and how can a drug company take advantage of FDA accelerated approval procedures? What are the labeling requirements for exporting approved drugs? How have the changes made by the FDA Safety and Innovation Act, including the Prescription Drug User Fee Act, the Generic Drug User Fee Amendments and the Biosimilars User Fee Act, and the Generating Antibiotic Incentives Now Act affected the overall statutory scheme? Generic and Innovator Drugs: A Guide to FDA Approval Requirements, Eighth Edition provides step-by-step guidance of the approval process and expert interpretation of: The Hatch-Waxman Act (Drug Price Competition and Patent Restoration Act) The Medicare Prescription Drug, Improvement, and Modernization Act The Food and Drug Administration Modernization Act The FDA Export Reform and Enhancement Act The Biologics Price Competition and Innovation Act And more! AUTHOR NOTE Donald O. Beersand’ contributions to this publication were completed before he rejoined the Food and Drug Administration. He has had no part in writing and revising this Eighth Edition.
Current Catalog
Author: National Library of Medicine (U.S.)
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1712
Book Description
First multi-year cumulation covers six years: 1965-70.
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1712
Book Description
First multi-year cumulation covers six years: 1965-70.
Psychotropic Durgs and Related Compounds
Author: National Institute of Mental Health (U.S.)
Publisher:
ISBN:
Category :
Languages : en
Pages : 808
Book Description
Publisher:
ISBN:
Category :
Languages : en
Pages : 808
Book Description
Drug Information
Author: Bonnie Snow
Publisher: Scarecrow Press
ISBN: 9780810833210
Category : Health & Fitness
Languages : en
Pages : 772
Book Description
Designed for use as a self-study text, as a course text in more formal instruction programs, or as a refresher for the busy professional, the book includes valuable background data on legal and regulatory issues, as well as pharmaceutical technology.
Publisher: Scarecrow Press
ISBN: 9780810833210
Category : Health & Fitness
Languages : en
Pages : 772
Book Description
Designed for use as a self-study text, as a course text in more formal instruction programs, or as a refresher for the busy professional, the book includes valuable background data on legal and regulatory issues, as well as pharmaceutical technology.
Drug Literature
Author: United States. Congress. Senate. Committee on Government Operations. Subcommittee on Reorganization and Internal Organizations
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 194
Book Description
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 194
Book Description
National Library of Medicine Current Catalog
Author: National Library of Medicine (U.S.)
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1170
Book Description
First multi-year cumulation covers six years: 1965-70.
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1170
Book Description
First multi-year cumulation covers six years: 1965-70.
Scientific Information Notes
Author:
Publisher:
ISBN:
Category : Research
Languages : en
Pages : 32
Book Description
Publisher:
ISBN:
Category : Research
Languages : en
Pages : 32
Book Description